IRIS
BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.668
AS - Asia 1.442
EU - Europa 1.028
SA - Sud America 392
AF - Africa 105
OC - Oceania 1
Totale 5.636
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.620
SG - Singapore 632
BR - Brasile 351
HK - Hong Kong 317
CN - Cina 282
IE - Irlanda 270
RU - Federazione Russa 231
SE - Svezia 163
IT - Italia 114
GB - Regno Unito 87
CI - Costa d'Avorio 65
VN - Vietnam 57
DE - Germania 44
IN - India 31
CA - Canada 23
FI - Finlandia 23
FR - Francia 20
PL - Polonia 18
ZA - Sudafrica 17
JP - Giappone 16
MX - Messico 16
TR - Turchia 16
AR - Argentina 15
AT - Austria 15
IQ - Iraq 15
BD - Bangladesh 14
UZ - Uzbekistan 10
UA - Ucraina 9
AE - Emirati Arabi Uniti 8
NL - Olanda 8
PK - Pakistan 8
ID - Indonesia 7
MA - Marocco 7
EC - Ecuador 6
VE - Venezuela 6
ES - Italia 5
AZ - Azerbaigian 4
CO - Colombia 4
JO - Giordania 4
KE - Kenya 4
LT - Lituania 4
SA - Arabia Saudita 4
BO - Bolivia 3
KG - Kirghizistan 3
NG - Nigeria 3
TN - Tunisia 3
BE - Belgio 2
BY - Bielorussia 2
CL - Cile 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
JM - Giamaica 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
PH - Filippine 2
PY - Paraguay 2
RS - Serbia 2
SN - Senegal 2
UY - Uruguay 2
AL - Albania 1
AU - Australia 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
GA - Gabon 1
GE - Georgia 1
HU - Ungheria 1
IR - Iran 1
KR - Corea 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
SV - El Salvador 1
TH - Thailandia 1
Totale 5.636
Salva come PNG Salva come JPEG
Città #
Ashburn 534
Singapore 394
Hong Kong 317
Chandler 297
Dublin 269
Dallas 171
Boardman 157
Fairfield 123
Lawrence 104
Princeton 104
New York 80
Beijing 75
Abidjan 65
San Diego 59
Los Angeles 55
The Dalles 53
Washington 53
Des Moines 49
Moscow 45
São Paulo 37
Seattle 32
London 30
Munich 26
Turin 24
Ho Chi Minh City 22
Redmond 21
Columbus 18
Chicago 17
Houston 17
Santa Clara 17
Tokyo 15
Turku 15
Hanoi 14
Johannesburg 13
Brooklyn 12
Hefei 12
Boston 11
Montreal 11
Pune 11
Rio de Janeiro 11
Warsaw 11
Belo Horizonte 10
Chennai 10
Guangzhou 10
Salt Lake City 10
Vienna 10
Ancona 9
Cambridge 9
San Francisco 9
Tashkent 9
Woodbridge 9
Shanghai 8
Atlanta 7
Brasília 7
Elk Grove Village 7
Helsinki 7
Manchester 7
Nuremberg 7
Poplar 7
Ankara 6
Baghdad 6
Denver 6
Jakarta 6
Phoenix 6
Porto Alegre 6
Ribeirão Preto 6
Contagem 5
Haiphong 5
Marche 5
Mexico City 5
Salvador 5
Sterling 5
Wilmington 5
Amman 4
Amsterdam 4
Baku 4
Bologna 4
Boydton 4
Casablanca 4
Changsha 4
Clifton 4
Detroit 4
Erbil 4
Fortaleza 4
Frankfurt am Main 4
Hangzhou 4
Hounslow 4
Macerata 4
Recife 4
Southwark 4
Toronto 4
Volta Redonda 4
Aparecida de Goiânia 3
Augusta 3
Bishkek 3
Buffalo 3
Caxias do Sul 3
Charlotte 3
Chiswick 3
Curitiba 3
Totale 3.730
Salva come PNG Salva come JPEG
Nome #
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 98
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 97
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 93
The application of cancer stem cell model in malignant mesothelioma 87
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 86
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 83
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 82
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 82
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 81
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 74
Cancer and the microbiome: Potential applications as new tumor biomarker 72
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 72
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 72
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 71
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 70
Sorafenib for the treatment of breast cancer 68
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 67
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 67
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 67
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes 65
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 65
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 65
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 65
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 64
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 64
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 64
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 63
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 62
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 62
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 62
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 62
Bortezomib: A new pro-apoptotic agent in cancer treatment 61
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 61
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 61
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 61
Germline copy number variation in the YTHDC2 gene: Does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 60
Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules 59
VIPoma and PPoma 58
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 58
New generation anaplastic lymphoma kinase inhibitors 58
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 58
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 57
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 57
A headlight on liquid biopsies: a challenging tool for breast cancer management 57
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 57
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 57
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 56
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 56
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 56
How much of familial breast cancer risk is currently explained by the known genes? 56
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 54
Fully human antibodies for malignant pleural mesothelioma targeting 54
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 51
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 50
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 49
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 49
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 48
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 48
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 48
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 47
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 46
The role of targeted therapy for gastrointestinal tumors 45
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 44
Dietary restriction: could it be considered as speed bump on tumor progression road? 44
Anti-endothelin drugs in solid tumors 44
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 44
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 43
EGFR genomic alterations in cancer: prognostic and predictive values 42
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 42
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 41
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 41
Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy 41
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 41
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 40
Magnetic Resonance Imaging and 99Tc WBC-SPECT/CT Scanning in Differential Diagnosis between Osteomyelitis and Charcot Neuroarthropathy: A Case Series 40
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 39
Monoclonal antibodies in gastrointestinal cancers 39
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 39
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 38
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 38
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 38
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 38
Relationship between imaging‐derived parameters and circulating microRNAs to study the degree of lung involvement in hospitalized geriatric patients with COVID‐19 pneumonia 37
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 37
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 37
Sex steroids, carcinogenesis, and cancer progression 37
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 36
Nintedanib in NSCLC: Evidence to date and place in therapy 36
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 35
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 35
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 34
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 34
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 34
Multisciplinary management of patients with liver metastasis from colorectal cancer 34
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 34
Targeted therapies in hepatocellular carcinoma 34
Colorectal cancer 34
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 33
Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach? 31
Targeting RET-rearranged non-small-cell lung cancer: Future prospects 31
Totale 5.384
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.510
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.510
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022515 0 0 0 0 0 0 0 0 237 13 153 112
2022/20231.116 106 67 91 59 78 196 2 55 343 5 81 33
2023/2024846 157 17 79 122 158 185 18 27 0 9 20 54
2024/20251.794 91 176 29 43 59 138 238 87 472 103 148 210
2025/20261.573 264 227 182 290 479 131 0 0 0 0 0 0
Totale 5.844